Metacrine is a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal (GI) diseases. Our most advanced programs target the farnesoid X receptor (FXR), which is central to modulating liver and GI diseases. FXR agonism has been investigated in large-scale clinical trials and has shown clinically relevant improvements in non-alcoholic steatohepatitis (NASH), a liver disease that affects 17 million people in the U.S. and is characterized by excess liver fat, inflammation and fibrosis. We believe that potency and continuous target engagement are key to optimizing therapeutic benefit with an FXR targeted therapy. Leveraging our extensive chemistry and biology expertise, we have built a proprietary library of over 2,500 FXR compounds, and have selected two oral FXR candidates from a unique chemical scaffold, MET409 and MET642. With our platform, we believe we can develop differentiated FXR agonist therapies for liver and GI diseases.
Company Details
- Employees
- 4
- Founded
- -
- Address
- 3985 Sorrento Valley Blvd,
- Phone
- (858) 369-7800
- in****@****ine.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- metacrine.com
- HQ
- San Diego, California
Metacrine, Inc. Questions
Metacrine, Inc.'s helpline number is (858) 369-7800
Metacrine, Inc.'s website is metacrine.com
Metacrine, Inc.'s LinkedIn profile is https://www.linkedin.com/company/metacrine-inc.
Metacrine, Inc. has
4 employees.
View email and phone details for 4
employees at Metacrine, Inc..
Metacrine, Inc.'s industry is
Biotechnology Research
Metacrine, Inc.'s top competitors are
Pacbio,
Mirador Therapeutics,
Vaxcyte,
Rayzebio,
Averto Medical, Inc,
Biotix,
Candid Therapeutics,
Omniome,
Belharra Therapeutics,
Primmune Therapeutics.
Metacrine, Inc.'s support email address is info@metacrine.com
Metacrine, Inc.'s categories are Biotechnology Research
Metacrine, Inc.'s founding year is 2014
